Another study by Long et al. [58] showed that AQP1-Abs are present in the majority of patients with NMO or at high risk of the disease (in 74.8% AQP4-IgG seropositive patients), but also in some patients with MS and rarely in patients with other neurological disorders [58]. Here, AQP4 is linked to myeloid sarcoma.